Agreement includes process development and commercial supply.

Human Genome Sciences (HGS) and Hospira signed an exclusive agreement for manufacturing process development and commercial supply of select Hospira biopharmaceutical products.

“We look forward to using our company’s world-class manufacturing facilities, quality systems, and process development capabilities to help advance and supply biopharmaceutical products for Hospira,” says said Curran Simpson, senior vp of operations at HGS.

Protein and antibody process development and manufacturing are core HGS competencies, adds Simpson. The company reports that it currently produces several protein and antibody drugs in two cGMP-compliant process development and manufacturing facilities, which total approximately 400,000 square feet and provide both small-scale and large-scale production in batches from 650 to 20,000 liters.

Previous articleP13 Kinase Pathway Controls Ebola’s Cell-Invasion Mechanism
Next articleMerck Serono Pays $14.4M Upfront in Deal with Ablynx